Comparisons Semaglutide vs Retatrutide

Semaglutide vs Retatrutide

Side-by-side comparison of weight loss results, pricing, side effects, and clinical data.

Semaglutide

~15%

Retatrutide

~24%

Head-to-Head Comparison

Metric
SemaglutideOzempic / Wegovy
RetatrutideNot yet approved
Drug Class
GLP-1 RA
GLP-1/GIP/Glucagon triple agonist
Administration
Weekly injection
Weekly injection
Dosing
Once weekly
Once weekly
Avg. Weight Loss
~15%
~24%
Half-Life
~7 days
~6 days
Compounded Cost
$150-400/mo (compounded)
Not yet available
Brand Cost
$1,000-1,400/mo
Not yet available
FDA Approved
2021
—
Key Trial
STEP 1 (16.9% weight loss)
Phase 2 (up to 24.2% weight loss at 48 weeks)

Side Effects Comparison

Semaglutide

  • Nausea
  • Diarrhea
  • Vomiting

Retatrutide

  • Nausea
  • Diarrhea
  • Vomiting

Pros & Cons

Semaglutide

Pros

  • +FDA-approved and available now
  • +Extensive clinical data
  • +Compounded versions available

Cons

  • -Less weight loss than retatrutide (based on early data)
  • -Single-receptor mechanism

Retatrutide

Pros

  • +Triple mechanism (GLP-1 + GIP + glucagon)
  • +Potentially greatest weight loss yet
  • +May preserve lean mass better

Cons

  • -Not FDA-approved
  • -Only Phase 2 data available
  • -Timeline to market uncertain

The Verdict

Retatrutide's Phase 2 data shows ~24% weight loss at 48 weeks — potentially exceeding even tirzepatide. However, it is not yet approved or available. Semaglutide is the proven, available option today. If retatrutide's Phase 3 trials confirm these results, it could become the most effective obesity medication.

No head-to-head trials yet. Retatrutide is in Phase 3 development by Eli Lilly.

Which Is Right for You?

Choose Semaglutide if...

Patients who need treatment now with a proven, available medication

Choose Retatrutide if...

Future option — currently only available through clinical trials

Frequently Asked Questions

When will retatrutide be available?

Retatrutide is currently in Phase 3 trials. If successful, FDA approval could come in 2026-2027. Until then, it is only available through clinical trials.

Is retatrutide better than semaglutide?

Early Phase 2 data suggests retatrutide may produce more weight loss (~24% vs ~15%), but Phase 3 data is needed to confirm. It also targets three receptors vs one for semaglutide.

How does the triple agonist mechanism work?

Retatrutide activates GLP-1 (appetite suppression), GIP (metabolic improvement), and glucagon (increased energy expenditure) receptors simultaneously, potentially creating a more comprehensive metabolic effect.

Find a provider prescribing Semaglutide or Retatrutide

Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.

Search Providers →

View all GLP-1 comparisons

Compare every major GLP-1 medication side by side. Weight loss data, cost analysis, and clinical trial results.

All Comparisons →